Leading Dutch biochip companies accelerate development of fast and reliable COVID-19 test.
April 23, 2020
Surfix B.V., together with its shareholders Qurin Diagnostics B.V. and LioniX International B.V., already successfully developing bio-photonic nanochips for cancer detection and other applications, today announce an accelerated development plan to allow mass-scale COVID-19 diagnosis and immunity detection with the financial support and in close collaboration with PhotonDelta.
The desktop testing device will yield reliable test results within 5 minutes and is scheduled to be available for commercial exploitation within 6-9 months. The device will be built around a photonic biochip using LioniX’ mature and proven silicon nitride based integrated optics technology (TriPleX™), a key technology within the PhotonDelta ecosystem. The surface functionalization and biochemical assay development are provided by Surfix and Qurin Diagnostics, respectively. The combination of these disciplines enables a successful, fast and accurate virus detection platform. The development will be supported by and in tight collaboration with Photon Delta (a Dutch public private partnership). The PhotonDelta support will be both in co-funding as in further future upscaling and exploitation.
Read the press release here.